Yizhi Li
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Integrated Analysis Reveals ZNF184 as a Novel Regulator of Stemness-Associated Paclitaxel Resistance and Tumor Progression in Breast Cancer.
Journal: Molecular carcinogenesis
Published: October 29, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Journal: Nature communications
Published: September 13, 2025
Applying a multi-task and multi-instance framework to predict axillary lymph node metastases in breast cancer.
Journal: NPJ precision oncology
Published: November 08, 2024
Identification of a Novel Substrate for eEF2K and the AURKA-SOX8 as the Related Pathway in TNBC.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 15, 2024
GPX4-AUTAC induces ferroptosis in breast cancer by promoting the selective autophagic degradation of GPX4 mediated by TRAF6-p62.
Journal: Cell death and differentiation
Published: October 08, 2024
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.
Journal: Med (New York, N.Y.)
Published: August 14, 2024
Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 23, 2024
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Journal: Cancer immunology, immunotherapy : CII
Published: December 25, 2023
Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
Journal: BMC cancer
Published: January 23, 2023
Identification of KCNK1 as a potential prognostic biomarker and therapeutic target of breast cancer.
Identification of KCNK1 as a potential prognostic biomarker and therapeutic target of breast cancer.
Journal: Pathology, research and practice
Published: July 22, 2022
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.
Journal: NPJ precision oncology
Published: July 28, 2021
Last Updated: 09/26/2026